Table 2 Uni- and multivariable analyses of factors associated with vancomycin resistance in clinical E. faecium isolates

 2012

(1.12–1.80)

0.004

(1.16–2.14)

0.004

 2013

(1.01–1.58)

0.044

(0.99–1.63)

0.061

 2014

–

–

–

–

 2015

(0.98–1.51)

0.072

(0.99–1.55)

0.060

 2016

(1.46–2.23)

< 0.001

(1.45–2.25)

< 0.001

 2017

(2.26–3.46)

< 0.001

(2.22–3.39)

< 0.001

 Southwest

–

–

–

–

 Southeast

(0.53–0.95)

0.022

(0.54–1.01)

0.057

 West

(0.46–1.00)

0.051

(0.55–1.20)

0.303

 Northwest

(0.35–0.61)

< 0.001

(0.36–0.72)

< 0.001

 Northeast

(0.27–0.67)

< 0.001

(0.31–0.71)

0.001

 Female

–

–

–

–

 Male

(0.90–1.06)

0.533

(0.94–1.11)

0.554

 0–19 years

(0.26–0.58)

< 0.001

(0.23–0.48)

< 0.001

 20–39 years

(0.71–1.01)

0.071

(0.71–0.99)

0.043

 40–59 years

–

–

–

–

 60–79 years

(0.82–1.12)

0.626

(0.83–1.06)

0.324

 80+ years

(0.67–1.10)

0.234

(0.69–1.01)

0.062

 Blood

–

–

–

–

 Urine

(0.92–1.52)

0.20276

(0.94–1.48)

0.134

 Swab

(0.78–1.51)

0.62974

(0.74–1.17)

0.547

 Wound

(0.93–1.36)

0.22761

(0.90–1.29)

0.426

 Other

(0.88–1.23)

0.65102

(0.85–1.19)

0.952

 Secondary care

–

–

–

–

 Tertiary care

(1.01–2.69)

0.047

(0.87–2.04)

0.191

 Specialist care

(1.15–5.56)

0.023

(1.22–4.60)

0.012

Prevention and rehabilitation care

(2.42–4.33)

< 0.001

(1.91–2.98)

< 0.001